Axonics Q1 2024 Earnings Report

Axonics EPS Results

• Actual EPS: -$0.38
• Consensus EPS: -$0.06
• Beat/Miss: Missed by -$0.32
• One Year Ago EPS: -$0.19

Axonics Revenue Results

• Actual Revenue: $91.41 million
• Expected Revenue: $89.79 million
• Beat/Miss: Beat by +$1.62 million
• YoY Revenue Growth: +29.40%

Axonics Announcement Details

• Quarter: Q1 2024
• Date: 4/30/2024
• Time: Q1 2024 Earnings Release

Axonics (NASDAQ:AXNX), a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.